Investors with a lot of money to spend have taken a bullish stance on Soleno Therapeutics SLNO. And retail traders should ...

三月对于美国FDA来说是一个繁忙的月份，预计有近十个药物的审批结果即将揭晓。这些药物涵盖了多种疾病领域，包括新一代抗生素治疗尿路感染、两种RNA干扰疗法等。以下是本月备受瞩目的几项重要审批动态： ...

One of the most highly anticipated FDA decisions this month is for Alnylam Pharmaceuticals, which is seeking to expand the ...

2 Paediatrics Academic Clinical Programme, Duke-NUS Medical School, Singapore 3 Paediatrics Academic Clinical Programme, Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore ...

Soleno Therapeutics ( ($SLNO) ) has released its Q4 earnings. Here is a breakdown of the information Soleno Therapeutics presented to its ...

New Drug Application (NDA) for diazoxide choline extended-release tablets (DCCR) for the treatment of Prader-Willi syndrome (PWS) accepted by the U.S. Food and Drug Administration (FDA) and granted ...

About Diazoxide Choline Extended-Release Tablets (DCCR)DCCR is a novel, proprietary extended-release dosage form containing the crystalline salt of diazoxide and is administered once-daily.